Fundus Albipunctatus

Segmenting retinal vessels plays a significant role in the diagnosis of fundus disorders. However, there are two problems in the retinal vessel segmentation methods. First, fine-grained features of fine blood vessels are difficult to be extracted. Second, it is easy to lose track of the details of blood vessel edges. To solve the problems above, the Residual SimAM Pyramid-Spatial Attention Unet (RSP-SA Unet) is proposed, in which the encoding, decoding, and upsampling layers of the Unet are mainly improved. Firstly, the RSP structure proposed in this paper approximates a residual structure combined with SimAM and Pyramid Segmentation Attention (PSA), which is applied to the encoding and decoding parts to extract multi-scale spatial information and important features across dimensions at a finer level. Secondly, the spatial attention (SA) is used in the upsampling layer to perform multi-attention mapping on the input feature map, which could enhance the segmentation effect of small blood vessels with low contrast. Finally, the RSP-SA Unet is verified on the CHASE_DB1, DRIVE, and STARE datasets, and the segmentation accuracy (ACC) of the RSP-SA Unet could reach 0.9763, 0.9704, and 0.9724, respectively. Area under the ROC curve (AUC) could reach 0.9896, 0.9858, and 0.9906, respectively. The RSP-SA Unet overall performance is better than the comparison methods.

Inherited retinal dystrophies encompass a diverse group of disorders affecting the structure and function of the retina, leading to progressive visual impairment and, in severe cases, blindness. Electrophysiology testing has emerged as a valuable tool in assessing and diagnosing those conditions, offering insights into the function of different parts of the visual pathway from retina to visual cortex and aiding in disease classification. This review provides an overview of the application of electrophysiology testing in the non-macular inherited retinal dystrophies focusing on both common and rare variants, including retinitis pigmentosa, progressive cone and cone-rod dystrophy, bradyopsia, Bietti crystalline dystrophy, late-onset retinal degeneration, and fundus albipunctatus. The different applications and limitations of electrophysiology techniques, including multifocal electroretinogram (mfERG), full-field ERG (ffERG), electrooculogram (EOG), pattern electroretinogram (PERG), and visual evoked potential (VEP), in the diagnosis and management of these distinctive phenotypes are discussed. The potential for electrophysiology testing to allow for further understanding of these diseases and the possibility of using these tests for early detection, prognosis prediction, and therapeutic monitoring in the future is reviewed.

Worldwide, age-related macular degeneration (AMD) is a multifactorial progressive fundus disorder that can cause vision impairment and severe central blindness in older adults. Currently, there are no approved prevention or treatment strategies for non-exudative AMD. While targeting VEGF is the main therapeutic approach to delay the degeneration process in exudative AMD, a significant number of patients show insensitivity or ineffectiveness to anti-VEGF therapy. Despite years of research, the exact mechanism underlying drusen formation and macular atrophy in AMD remains unknown. In the pathogenesis of AMD, lncRNAs play crucial roles, as discussed in this paper. This review focuses on the function of dysregulated lncRNAs and the mechanisms by which specific molecules target these lncRNAs in AMD. The analysis reveals that lncRNAs primarily regulate the progression of AMD by mediating apoptosis, epithelial-mesenchymal transition (EMT), dedifferentiation, and oxidative stress in choroidal vascular endothelial cells, retinal pigment epithelium (RPE) cells, and photoreceptors. Consequently, the regulation of apoptosis, dedifferentiation, EMT, and other processes by lncRNAs has emerged as a crucial focus in AMD research.These findings contribute to our understanding of the role of lncRNAs in AMD and their potential as valuable biomarkers. Furthermore, they highlight the need for further basic and clinical studies to explore the value of lncRNAs as biomarkers and potential therapeutic targets for AMD.